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calciﬁcation. As can be seen from the 
anatomy of the auricle, the presence of 
chondrocytes does not necessarily mean 
the development of endochondral bone 
formation. Furthermore, calciﬁed and 
non-calciﬁed portions are clearly sepa-
rate in the bone. Thus, the time course 
needs to be demonstrated, and the initial 
mechanisms that trigger the transition 
from cartilage to bone tissue within the 
vessel wall need to be identiﬁed.
If medial calcification also involves 
the processes of endochondral bone for-
mation, another major issue remains to 
be clariﬁed. What are the essential dif-
ferences in the pathogenesis of calciﬁ-
cation in the intima and in the media? 
Because medial calciﬁcation is often seen 
in the elderly and in patients with CKD 
or diabetes, a number of factors have 
been examined, such as uremic tox-
ins, oxidative stress, and inﬂammation; 
however, they fail to explain the diﬀer-
ences clearly. Future breakthroughs are 
certainly required to establish eﬀective 
prevention and treatment modalities for 
medial calciﬁcation in CKD patients.
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Can we do better than a single 
estimated GFR threshold when 
screening for chronic kidney 
disease?
ED Poggio1 and AD Rule2
The Modification of Diet in Renal Disease (MDRD) equation has been 
used to screen for and diagnose chronic kidney disease (CKD). A fixed 
estimated glomerular filtration rate cutoff point has been advocated 
by the National Kidney Foundation to diagnose CKD. However, data 
derived from healthy individuals challenge this approach and suggest 
that age- and gender-specific reference values may be more useful in the 
screening setting.
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The publication of the Kidney Disease 
Outcomes Quality Initiative (KDOQI) 
guidelines by the National Kidney Founda-
tion (NKF) in 2002 provided the medical 
community for the ﬁrst time with a uni-
form deﬁnition of chronic kidney disease 
(CKD).1 These guidelines had the objec-
tive of timely management and treatment 
of this population at risk for increased 
mortality. This classiﬁcation of CKD is 
based on three fundamental components: 
(1) an anatomical or structural component 
as evidenced by the presence of parenchy-
mal renal disease (for example, abnormal 
imaging testing, abnormalities of the urine 
composition, and so on); (2) a temporal 
component in which the abnormalities 
are present for at least 3 months; and (3) a 
functional component based on glomeru-
lar ﬁltration rate (GFR). Although all three 
are critical, the level of GFR is the pivot for 
staging the disease and determining the 
applicability of the recommended KDOQI 
treatment and management guidelines. 
Because direct GFR measurements are 
expensive and inconvenient, estimated 
GFR (eGFR) by the abbreviated Modiﬁ-
cation of Diet in Renal Disease (MDRD) 
equation has been the tool chosen by the 
NKF.1 An important consideration is that 
these guidelines deﬁne and classify CKD 
irrespective of cause of renal disease and 
make no distinction based on gender and 
age.2 For example, patients with stage 
3 CKD (eGFR 30–59 ml/min/1.73 m2) 
are lumped together even though they 
represent a wide spectrum of ‘disease’ 
from a 35-year-old man with a progres-
sive glomerulonephritis to a 65-year-old 
woman without risk factors for CKD but 
with a high-normal serum creatinine 
level.
The MDRD equation was developed 
from nephrology referral patients identi-
ﬁed by an elevated serum creatinine level 
(≥1.2 mg/dl in women and ≥1.4 mg/dl in 
men).3 To emphasize an early diagnosis of 
CKD, the NKF and the National Kidney 
Disease Education Program (NKDEP) 
generalized the use of the equation and 
recommend that all laboratories automati-
cally report an eGFR with each serum cre-
atinine test measured, irrespective of the 
clinical setting in which the test has been 
see original article on page 632
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ordered. Thus, the MDRD equation is 
implicitly being used as a screening tool 
to detect CKD in the general population, 
most of whom are normal healthy people. 
Although this equation has been found to 
perform very well in patients with elevated 
serum creatinine levels, this tool underes-
timates GFR in populations characterized 
by normal serum creatinine levels.4,5 Rec-
ognizing limitations in the application of 
the MDRD equation as a screening test, 
the NKF and NKDEP recommend report-
ing exact eGFR values if the eGFR is below 
60 ml/min/1.73 m2, and limiting the report 
to ‘>60 ml/min/1.73 m2’ if it is above this 
cutoﬀ value.6
When screening for disease, it is impor-
tant to recognize that health is a relative 
condition that does not have a universally 
accepted deﬁnition. There are generally 
two approaches used to define disease 
thresholds: the ﬁrst is the ‘critical value’ at 
which increased morbidity and mortal-
ity occur, and the second is the ‘health-
associated reference value.’7 In this issue 
of Kidney International, Wetzels et al.8 
use this latter approach by deﬁning refer-
ence values for eGFR based on the MDRD 
equation using a cross-sectional sample of 
a healthy population in the Netherlands. 
The authors report that a significant 
minority of healthy subjects, mostly older 
and female subjects, have indeed an eGFR 
below 60 ml/min/1.73 m2, the recom-
mended cutoﬀ to categorize a subject as 
having CKD. Conversely, many younger, 
and particularly male, subjects have a 
threshold above 60 ml/min/1.73 m2. 
Importantly, the authors calibrated the 
creatinine values obtained by their labora-
tory to the one used by the original MDRD 
laboratory to minimize bias.
The result of this work questions the def-
inition of CKD solely based on an eGFR of 
less than 60 ml/min/1.73 m2 irrespective 
of age or clinical setting. As shown in Table 
1, the age- and sex-speciﬁc lower limit of 
normal for eGFR (5th percentile) in the 
study by Wetzels et al.8 is equivalent to the 
sex-speciﬁc upper limit of normal (95th 
percentile) for serum creatinine (1.3 mg/dl 
in men and 1.1 mg/dl in women for ages 
less than 70 years). This is a very similar 
threshold to that used to identify the par-
ticipants for deriving the MDRD equa-
tion. This is also consistent with studies 
using kidney donors to represent health, 
in that the upper limit of normal for serum 
creatinine did not vary with age and was 
approximately 0.2 mg/dl higher in men 
than in women.9 After age 70 years, when 
occult disease is highly prevalent, a ques-
tionnaire, such as that used by Wetzels et 
al.,8 to classify health may be inadequate, 
and the upper limit of normal for serum 
creatinine is less clear.
This contrasts with the setting of care for 
patients with known and established kid-
ney disease, where information regarding 
the severity of kidney dysfunction by eGFR 
is more useful than serum creatinine alone. 
The improved performance of the MDRD 
equation in this setting is largely due to the 
statistical modeling of muscle mass with 
the surrogate markers: age, sex, and race. 
In contrast, when the MDRD equation is 
used to screen patients for CKD, the equa-
tion is inherently ﬂawed, because age, sex, 
and race are not simply surrogate mark-
ers of muscle mass, but also markers of 
CKD risk. One could argue that, for the 
care of a healthy subject with no identi-
ﬁable risk factors for CKD and no blood 
or urine chemistry abnormalities, exact 
knowledge of the degree of GFR is not 
clinically crucial. The current recommen-
dation by the NKF is to report exact val-
ues only when below 60 ml/min/1.73 m2, 
but this approach is circular, because the 
clinician has already assumed the patient 
has CKD by applying the MDRD equation 
(Figure 1a).10,11 A more defensible posi-
tion proposed by Wetzels et al.8 is to use 
a reference-value eGFR to deﬁne CKD, 
because eGFR levels below the lower ref-
erence threshold are much less plausible 
Figure 1 | Approaches to screen for CKD. (a) ‘Critical value-based.’  The current approach advocated by the National Kidney Foundation is based on a 
critical value for eGFR (60 ml/min/1.73 m2) at which increased morbidity and mortality are perceived to occur. Estimation of GFR from serum creatinine 
varies depending on assumptions of health or CKD. (b) ‘Healthy reference value-based.’  This alternative approach is based on healthy reference values 
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for healthy persons (Figure 1b). There are 
two important caveats to consider. First, 
the lower limit of normal for MDRD equa-
tion eGFR is substantially diﬀerent from 
the lower limit of normal for a direct GFR 
measurement. For example, by MDRD 
eGFR, Wetzels et al.8 found the lower 
limit of normal (5th percentile) to be 72–
77 ml/min/1.73 m2 in a 20-year-old and 
51–57 ml/min/1.73 m2 in a 65-year-old. 
This is far below the lower limit of normal 
for a direct GFR measurement of 91 ml/
min/1.73 m2 in a 20-year-old and 69 ml/
min/1.73 m2 in a 65-year-old,9 because 
age, sex, and race inadequately model 
interindividual variability in muscle mass 
and because there are likely diﬀerences 
in muscle mass between healthy persons 
and CKD patients.10 The second caveat is 
that the commonly reported upper limit 
of normal for serum creatinine (1.3 mg/
dl in men and 1.1 mg/dl in females) pro-
vides equivalent information (Table 1). In 
essence, the proposal by Wetzels et al.8 is 
similar to using serum creatinine reference 
values to deﬁne CKD.
Nevertheless, the work by Wetzels et al.8 
brings up a very important point: the use 
of a single threshold for GFR is inappro-
priate to deﬁne CKD. Both longitudinal 
and cross-sectional studies have shown 
that GFR declines with normal aging by 
approximately 5–10 ml/min per decade.9 
As the data of Wetzels et al.8 suggest, a sig-
niﬁcant minority of the studied population 
believed to be healthy would be considered 
to have the diagnosis of stage 3 CKD just 
by the sole ﬁnding of a decreased eGFR. As 
is pointed out above, the MDRD equation, 
even when calibrated serum creatinine val-
ues are used, is likely to underestimate the 
GFR in healthy subjects and thus increase 
the risk of misdiagnosing healthy subjects 
with CKD. It has been argued that despite 
inaccuracy with equations, an eGFR less 
than 60 ml/min/1.73 m2 should be used 
to deﬁne CKD, because this ‘critical value’ 
predicts morbidity and mortality. How-
ever, recent data do not fully support this 
threshold. Epidemiological data derived 
from large managed-care populations 
limited to patients with multiple and stable 
serum creatinine levels found no increased 
adjusted risk of mortality in subjects with 
an eGFR of 50–59 ml/min/1.73 m2 com-
pared with subjects with an eGFR of 
60 ml/min/1.73 m2 or higher.12,13 In fact, 
in one study a stable eGFR of 50–59 ml/
min/1.73 m2 in older subjects was associ-
ated with a lower adjusted risk of mortal-
ity than an eGFR of 60 ml/min/1.73 m2 or 
higher.13 The problem is that eGFR based 
on serum creatinine is itself a marker of 
muscle mass and thus ﬁtness. A decreased 
true GFR will probably predict increased 
mortality, but the increased muscle mass 
reﬂected by a decreased eGFR may be pro-
tective against mortality. Moreover, recent 
data have also found that CKD complica-
tions (anemia, hyperphosphatemia, acido-
sis) are relatively uncommon in the general 
population for persons with an eGFR of 
30–59 ml/min/1.73 m2.14 In conclusion, 
the work by Wetzels et al.8 provides further 
support for considering age- and gender-
speciﬁc serum creatinine or eGFR values 
when screening for CKD.
REFERENCES
1. Levey AS, Coresh J, Balk E et al. National Kidney 
Foundation practice guidelines for chronic kidney 
disease: evaluation, classification, and stratification 
[published erratum appears in Ann Intern Med 
2003; 139: 605]. Ann Intern Med 2003; 139: 137–
147.
2. Chen ML, Hsu CY. Should the K/DOQI definition of 
chronic kidney disease be changed? Am J Kidney 
Dis 2003; 42: 623–625.
3. Kusek JW, Coyne T, de Velasco A et al. Recruitment 
experience in the full-scale phase of the 
Modification of Diet in Renal Disease Study. Control 
Clin Trials 1993; 14: 538–557.
4. Poggio ED, Wang X, Greene T et al. Performance 
of the Modification of Diet in Renal Disease and 
Cockcroft-Gault Equations in the estimation of GFR 
in health and in chronic kidney disease.  
J Am Soc Nephrol 2005; 16: 459–466.
5. Rule AD, Larson TS, Bergstralh EJ et al. Using serum 
creatinine to estimate glomerular filtration rate: 
accuracy in good health and in chronic kidney 
disease. Ann Intern Med 2004; 141: 929–937.
6. Suggestions for Laboratories. National Kidney 
Disease Education Program. <http://www.nkdep.
nih.gov/resources/laboratory_reporting.htm> 
(2003).
7. National Committee for Clinical Laboratory 
Standards (NCCLS). How to define and determine 
reference intervals in the clinical laboratory: 
approved guideline — second edition. In: NCCLS 
document C28-A2 (ISBN 1562384066), NCCLS, 
Wayne, Pennsylvania, USA, 2000.
8. Wetzels JFM, Kiemeney LALM, Swinkels DW et 
al. Age- and gender-specific reference values 
of estimated GFR in Caucasians: the Nijmegen 
Biomedical Study. Kidney Int 2007; 72: 632–637. 
9. Rule AD, Gussak HM, Pond GR et al. Measured and 
estimated GFR in healthy potential kidney donors 
[published erratum appears in Am J Kidney Dis 
2004; 44: 1126]. Am J Kidney Dis 2004; 43: 112–119.
10. Rule AD. Understanding estimated glomerular 
filtration rate: implications for identifying chronic 
kidney disease. Curr Opin Nephrol Hypertens 2007; 
16: 242–249.
11. Rule AD, Rodeheffer RJ, Larson TS et al. Limitations 
of estimating glomerular filtration rate from serum 
creatinine in the general population. Mayo Clin Proc 
2006; 81: 1427–1434.
12. Go AS, Chertow GM, Fan D et al. Chronic kidney 
disease and the risks of death, cardiovascular 
events, and hospitalization. N Engl J Med 2004; 351: 
1296–1305.
13. O’Hare AM, Bertenthal D, Covinsky KE et al. 
Mortality risk stratification in chronic kidney 
disease: one size for all ages? J Am Soc Nephrol 
2006; 17: 846–853.
14. Clase CM, Kiberd BA, Garg AX. Relationship 
between glomerular filtration rate and the 
prevalence of metabolic abnormalities: results 
from the Third National Health and Nutrition 
Examination Survey (NHANES III). Nephron Clin 
Pract 2007; 105: c178–c184.
Table 1 | Upper limit of normal for serum creatinine calculated from the lower limit of normal 





Male eGFR 5th 
percentilea




Female SCr 95th 
percentile 
18–24 21 77 1.3 72 1.0
25–29 27 74 1.2 63 1.1
30–34 32 68 1.3 63 1.1
35–39 37 65 1.3 63 1.0
40–44 42 66 1.3 58 1.1
45–49 47 63 1.3 56 1.1
50–54 52 60 1.3 56 1.1
55–59 57 58 1.3 53 1.1
60–64 62 59 1.3 50 1.2
65–69 67 56 1.4 52 1.1
70–74 72 54 1.4 49 1.2
75–79 77 45 1.6 45 1.2
80–84 82 43 1.6 46 1.2
aWetzels et al.8 SCr, serum creatinine.
